Veronique Maguer-Satta

List of Publications by Year
in descending order

70	2,487	186265	206112
papers	citations	28 h-index	48 g-index

76	76	76	4135
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A minimal standardized human bone marrow microphysiological system to assess resident cell behavior during normal and pathological processes. Biomaterials Science, 2022, 10, 485-498.	5.4	1
2	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia. Blood Advances, 2022, 6, 3611-3624.	5.2	6
3	Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Frontiers in Immunology, 2021, 12, 766275.	4.8	13
4	ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular Metabolism, 2021, 55, 101410.	6.5	3
5	Altered BMP2/4 Signaling in Stem Cells and Their Niche: Different Cancers but Similar Mechanisms, the Example of Myeloid Leukemia and Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 787989.	3.7	6
6	A new agarose-based microsystem to investigate cell response to prolonged confinement. Lab on A Chip, 2020, 20, 4016-4030.	6.0	8
7	Single-cell analysis of autophagy activity in normal and de novo transformed human mammary cells. Scientific Reports, 2020, 10, 20266.	3.3	2
8	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. Frontiers in Oncology, 2020, 10, 712.	2.8	13
9	The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nature Cancer, 2020, 1, 672-680.	13.2	132
10	Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 1540-1552.	7.2	46
11	The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. Haematologica, 2020, 106, 111-122.	3.5	22
12	Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia. Biochemical Society Transactions, 2020, 48, 411-418.	3.4	14
13	Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins. Cancers, 2019, 11, 1351.	3.7	9
14	Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells. Cell Proliferation, 2019, 52, e12611.	5.3	11
15	The BMP pathway: A unique tool to decode the origin and progression of leukemia. Experimental Hematology, 2018, 61, 36-44.	0.4	33
16	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Journal of the National Cancer Institute, 2018, 110, 467-478.	6.3	76
17	A new signaling cascade linking BMP4, BMPR1A, Î”Np73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death and Disease, 2018, 9, 1011.	6.3	28
18	Developmental and cancer-associated plasticity of DNA replication preferentially targets GC-poor, lowly expressed and late-replicating regions. Nucleic Acids Research, 2018, 46, 10157-10172.	14.5	30

#	Article	IF	Citations
19	The critical role of the <scp>ZNF217</scp> oncogene in promoting breast cancer metastasis to the bone. Journal of Pathology, 2017, 242, 73-89.	4.5	42
20	Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Blood, 2017, 130, 2860-2871.	1.4	35
21	Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling. Cell Death and Differentiation, 2017, 24, 155-166.	11.2	39
22	Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence. Stem Cell Investigation, 2017, 4, 67-67.	3.0	30
23	T315I+ tyrosine-kinase independent CML cells resistance. Oncotarget, 2017, 8, 43600-43601.	1.8	1
24	Blocking TGF-Î² and BMP SMAD-dependent cell differentiation is a master key to expand all kinds of epithelial stem cells. Stem Cell Investigation, 2016, 3, 88-88.	3.0	8
25	Enlightening intracellular complexity of living cells with quantitative phase microscopy. , 2016, , .		3
26	BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche. Molecular and Cellular Oncology, 2016, 3, e1026527.	0.7	13
27	Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response. Stem Cell Reports, 2015, 4, 239-254.	4.8	54
28	Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematology,the, 2015, 2, e37-e46.	4.6	45
29	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	2.8	239
30	The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis, 2015, 36, S160-S183.	2.8	97
31	Local Mitochondrial-Endolysosomal Microfusion Cleaves Voltage-Dependent Anion Channel 1 To Promote Survival in Hypoxia. Molecular and Cellular Biology, 2015, 35, 1491-1505.	2.3	40
32	The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. Leukemia, 2015, 29, 1993-2002.	7.2	56
33	Deciphering the internal complexity of living cells with quantitative phase microscopy: a multiscale approach. Journal of Biomedical Optics, 2015, 20, 096005.	2.6	22
34	Quantifying Epithelial Early Common Progenitors from Longâ€Term Primary or Cell Line Sphere Culture. Current Protocols in Stem Cell Biology, 2015, 35, 1E.7.1-1E.7.8.	3.0	1
35	Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood, 2013, 122, 3767-3777.	1.4	76
36	The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica, 2013, 98, 1510-1516.	3.5	61

#	Article	IF	Citations
37	Sex differences in the GSK3Î²-mediated survival of adherent leukemic progenitors. Oncogene, 2012, 31, 694-705.	5.9	24
38	A Protocol to Quantify Mammary Early Common Progenitors from Longâ€Term Mammosphere Culture. Current Protocols in Stem Cell Biology, 2012, 20, Unit 1E.7.	3.0	5
39	Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, 2011, 117, 1673-1676.	1.4	51
40	Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer. Stem Cells, 2011, 29, 389-396.	3.2	151
41	Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leukemia Research, 2011, 35, 38-43.	0.8	17
42	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research, 2011, 35, 448-458.	0.8	17
43	CD10: A tool to crack the role of stem cells in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1264-E1264.	7.1	7
44	TP63 P2 promoter functional analysis identifies Î²-catenin as a key regulator of Î”Np63 expression. Oncogene, 2011, 30, 4656-4665.	5.9	26
45	The CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells. Stem Cells, 2010, 28, 1081-1088.	3.2	72
46	Cancer Stem Cells: The Emerging Challenge of Drug Targeting. Current Medicinal Chemistry, 2009, 16, 394-416.	2.4	64
47	Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia, 2008, 22, 2131-2134.	7.2	16
48	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood, 2008, 112, 3154-3163.	1.4	47
49	A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin. Experimental Cell Research, 2006, 312, 434-442.	2.6	24
50	FLRG, a new ADAM12â€associated protein, modulates osteoclast differentiation. Biology of the Cell, 2005, 97, 577-588.	2.0	24
51	Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma. European Journal of Endocrinology, 2004, 151, 251-257.	3.7	20
52	Human endometrium and decidua express follistatin-related gene (FLRG) mRNA and peptide. Molecular and Cellular Endocrinology, 2004, 218, 129-135.	3.2	21
53	FLRG, member of the follistatin family, a new player in hematopoiesis. Molecular and Cellular Endocrinology, 2004, 225, 109-118.	3.2	36
54	In vitro Use of Primary Human Hematopoietic Cells as a Model to Investigate the Regulation of Erythropoiesis. Transfusion Medicine and Hemotherapy, 2004, 31, 33-40.	1.6	4

#	Article	IF	Citations
55	Human placenta and fetal membranes express follistatin-related gene mRNA and protein. Journal of Endocrinological Investigation, 2003, 26, 641-645.	3.3	29
56	Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFÎ² family. Experimental Cell Research, 2003, 282, 110-120.	2.6	89
57	Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood, 2002, 99, 4647-4649.	1.4	42
58	Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene, 2002, 21, 2227-2235.	5.9	79
59	FLRG, an activin-binding protein, is a new target of TGFÎ² transcription activation through Smad proteins. Oncogene, 2001, 20, 5409-5419.	5.9	42
60	During hematopoiesis, expression of FLRG, a novel activin A ligand, is regulated by TGF-Î². Experimental Hematology, 2001, 29, 301-308.	0.4	47
61	Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. Blood, 2000, 96, 4118-4123.	1.4	18
62	Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. Blood, 2000, 96, 4118-4123.	1.4	3
63	Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein. Gene Therapy, 1998, 5, 556-562.	4.5	17
64	BCRâ€‰â€“â€‰ABL accelerates C2-ceramide-induced apoptosis. Oncogene, 1998, 16, 237-248.	5.9	46
65	Ex Vivo Cytokine Expansion of Peripheral Blood Ph-Negative Cells in Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1998, 32, 151-157.	1.3	5
66	BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood, 1996, 88, 1796-1804.	1.4	54
67	BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood, 1996, 88, 1796-1804.	1.4	1
68	Human immature thymocytes as target cells of the leukemogenic activity of human T-cell leukemia virus type I. Blood, 1995, 86, 1444-1452.	1.4	23
69	Pancreatic Lymph Nodes are Early Targets of T Cells during Adoptive Transfer of Diabetes in NOD Mice. Journal of Autoimmunity, 1995, 8, 323-334.	6.5	35
70	A Potential New Mechanism for Bisphenol Molecules to Initiate Breast Cancer through Alteration of Bone Morphogenetic Protein Signaling in Stem Cells and Their Microenvironment. , 0, , .		0